Authors

FDA’s New Accelerated Approval Draft Guidance

What biopharma companies need to know about this evolving regulatory pathway.

Why Healthcare Costs are Surging—And What to Do About it

Identifying the inflators and deflators, and the role all stakeholders play.

Advancing Circular Economy Packaging in Pharmaceutical Cold Chain

Site Satisfaction Is the New Competitive Advantage

Clinical trial sites face persistent payment delays and complex processes, risking their viability and impacting drug development. Solutions prioritize transparency and flexibility.

TrumpRX Has a Blind Spot and It Can Redefine Patient Access

TrumpRx’s promised drug-price cuts expose a deeper systemic flaw, positioning direct-to-patient clinical pathways as the infrastructure pharma must build to turn political headlines into real access and outcomes.

Bridging the Precision Gap: Accelerating Clinical Adoption of Companion Diagnostics in Oncology

Companion diagnostics are reshaping precision oncology, but clinical adoption continues to lag behind scientific progress due to regulatory, operational and reimbursement barriers.

The Competitive Edge in Pharma Logistics: Sustainability, Safety, and Precision Delivery

Realtime Electronic Data Capture at Investigator Sites: Laboratory Data and Beyond

Beyond Awareness: Modeling Shared Decision-Making in Patient Communications

When patients struggle to see a positive path forward, modeling a constructive journey can give them the confidence they need.

Impact, Access, and Scale: The Potential of India’s Pharma Market

Country is poised to offer growth-channel opportunities for global pharma companies ready to scale access, innovation, and profitability.

AI in Drug Discovery On-Demand Webinar

The Insight Gap: Biopharma’s Hidden Risk in the Race Against the Patent Cliff

The looming patent cliff exposes a deeper industry challenge, as biopharma companies face up to $400 billion in at-risk revenue while struggling to translate abundant data into actionable insight needed to compete in increasingly crowded markets.

Revolutionizing Pharma Patient Assistance Programs, KnippeRx Leads the Future of Patient Care

Impact, Access, and Scale: The Potential of India’s Pharma Market

Country is poised to offer growth-channel opportunities for global pharma companies ready to scale access, innovation, and profitability.

The Shifting Pharmacy Landscape in 2025

Polypharmacy, biosimilars, and GLP-1s among the evolving trends likely to play out in the pharmacy benefits space.

The Ways Pharma Leaders are Rewiring their Organizations for Launch Success

Going Beyond Compliance: Early Adoption of FDA’s Quality Management Maturity Program—and the Practical Considerations for Executives

An examination of proactive preparedness and readiness review for future enrollment in the agency’s QMM program—now in the pilot stage as an effort to incentivize pharma manufacturers to achieve a more mature state of quality culture.

Q&A: Supply Chain Fallout From Iran War, Tariff Uncertainty

Dan Bell, chief strategy officer at Marken, discusses how biopharma companies and logistics teams are responding to the dual disruptors to global supply chain operations.

The Questions You Couldn’t Ask in Time: How Agentic AI Accelerates Market Entry

Agentic AI is reshaping pharma market entry by enabling real-time, data-driven insights that allow companies to ask more complex strategic questions and act faster — with greater precision.

Rethinking Audience Modeling: AI, Regulations, & More

The intersection of artificial intelligence and direct-to-consumer advertising presents unprecedented opportunities and evolving challenges as regulations and technologies reshape the biopharma landscape.

How AI is Shaping KOL and DOL Identification

As drugmakers navigate an increasingly complex terrain of scientific and digital influence, the ability to accurately identify and understand both key and digital opinion leaders is vital for effective engagement.

Global leader in engagement with healthcare stakeholders

HEOR: From Proving Product Value to Proving Its Own Worth

The recent shift in Health Economics and Outcomes Research functions across major pharmaceutical companies highlights a lack of understanding of its value.

Beyond the Prescription: The Role Pharma Plays in Digital Health Conversations

As social media continues to influence healthcare communication, it presents both challenges and opportunities for the pharmaceutical industry. In this interview, Jennifer Harakal of Canopy Life Sciences discusses balancing compliance with effective digital engagement to build trust and facilitate meaningful healthcare conversations.

Beyond the Data: Making HCP Analytics Actually Work for Commercial Teams

Traditional approaches to HCP segmentation are no longer sufficient. The challenge now is to maintain personalization at scale while managing large territories and diverse customer bases.

How Does the Shift to Early-Stage M&A Change Due Diligence?

A well-defined scientific and strategic approach is critical for buyers in this dealmaking setting.

Why 75 Top Pharma Execs Are Ditching Fragmented Marketing Stacks

At the Doceree Makers Summit, leaders from Sanofi, Bristol Myers Squibb, Eli Lilly, and others backed a new pharma marketing operating model to replace fragmented legacy softwares.

Realtime Electronic Data Capture at Investigator Sites: Laboratory Data and Beyond

Making an Impact in the Era of Disinformation

With increasing cases of disinformation across social media blurring the lines of what’s credible and real, how can pharma break through the noise and build back public trust?

China’s Trial Advantage: Tracking Nation’s Growth in Pharma Innovation and Global Investment

A look at China's emergence as a hub for novel treatment pursuits—and ways international investors can best capitalize on the favorable research trajectory.